Pharmaceuticals

Phibro Animal Health

Phibro Animal Health released FY2026 9 Months earnings on May 6 After-Market EST, actual revenue USD 1.121 B, actual EPS USD 1.91

Phibro Animal Health released FY2026 Q3 earnings on May 6 After-Market EST, actual revenue USD 383.54 M (forecast USD 367.02 M), actual EPS USD 0.59 (forecast USD 0.57)

Phibro Animal Health to release FY2026 Q3 earnings on May 6 After-Market EST, forecast revenue USD 367.02 M, EPS USD 0.57

Phibro Animal Health Corp Reports Strong Second-Quarter Performance

Phibro Animal Health released FY2026 Semi-Annual Earnings on February 4 After-Market EST, with actual revenue of USD 737.8 M and EPS of USD 1.32

Phibro Animal Health released FY2026 Q2 earnings on February 4 After-Market (EST), actual revenue USD 373.91 M (forecast USD 355.64 M), actual EPS USD 0.67 (forecast USD 0.35)

Phibro Animal Health to Release FY2026 Q2 Earnings on February 4 After-Market (EST), Forecast Revenue USD 355.64 M, EPS USD 0.35

Phibro Animal Health released FY2026 Q1 earnings on November 5 After-Market (EST), actual revenue USD 363.89 M (forecast USD 345.44 M), actual EPS USD 0.65 (forecast USD 0.38)

Phibro Reports Q1 Net Sales Growth of 40%, Exceeding Analyst Expectations

Phibro Animal Health to Release FY2026 Q1 Earnings on November 5 After-Market EST, Forecast Revenue USD 345.44 M, EPS USD 0.38

Phibro Animal Health released FY2025 Q4 earnings on August 27 After-Market EST, actual revenue USD 378.7 M (forecast USD 362.24 M), actual EPS USD 0.4252 (forecast USD 0.37)

Phibro Animal Health released FY2025 Annual Earnings on August 27 After-Market (EST), actual revenue USD 1.296 B (forecast USD 1.278 B), actual EPS USD 1.19 (forecast USD 1.09)

Phibro Animal Health to Release FY2025 Q4 Earnings on August 27 After-Market EST, Forecast Revenue USD 362.24 M, EPS USD 0.37

JPMorgan Raises Phibro Animal Health's Rating

Morgan Stanley Maintains Phibro Animal Health Rating and Adjusts Target Price

Phibro Animal Health Co. Upgraded by Analysts

Axecap Increases Stake in Phibro Animal Health

Jane Street Group LLC Reduced Holdings in Phibro Animal Health Co.

Kings Path Partners LLC Increased Holdings in Phibro Animal Health

Morgan Stanley Raises PHIBRO ANIMAL HEALTH CORP Price Target

OPTIMI HEALTH CORP

HCW Biologics

GCL Global

Silexion Therapeutics

MetaVia

Vida Global

Micware

BiomX

Tradr 2X Long XNDU Daily ETF

EMMIS ACQUISITION CORP. ORD USD0.0001 (S/R 12/09/2030)

Ordinary dividend (cash)

Ex Date: 2026.06.03 (EST), Cash dividend 0.12 USD

PAHC

Phibro Animal Health reported a 10% increase in Q3 2026 net sales to USD 383.5 million and an 11% rise in adjusted EBITDA to USD 60 million. The company tightened its full-year guidance for net sales and adjusted EBITDA. Brazil's new antimicrobial regulations may impact future sales, particularly for virginiamycin. Liquidity improved with a USD 125 million credit facility upsizing, and the company is focusing on its Verratain sustainability platform.

PUBT

JPMorgan Chase

Citigroup

JPMORGAN CHASE & CO. 4.20% DEP SHS REPSTG 1/400TH PFD SER MM

JPMORGAN CHASE & CO. 6%NON CUM DEP SHS REP 1/400TH PFD SER EE

JPMORGAN CHASE & CO. DEP REP 1/400TH (5.75% NON CUM PFD DD)

JPMORGAN CHASE & CO. 4.625% DEP SH RE 1/400TH INT NO CU PF LL

JPMorgan Chase & Co.

JPMORGAN CHASE & CO. 4.55% DEP SHS REPSTG 1/400TH PFD SER JJ

JPMORGAN CHASE & CO. 4.75 DEP SHS REP 1/400 NCUM PFD SR GG

CITIGROUP INC 6.250 NON CUM SER II PFD WI

Phibro Animal Health posts transcript of Q3 2026 earnings call

Phibro Animal Health (NASDAQ: PAHC) reported a strong fiscal Q3 2026, with net sales rising 10% to $383.5 million and adjusted EBITDA increasing 11% to $60 million. The Animal Health segment led growth, with net sales up 13%. However, Performance Products saw a 17% decline in sales. The company updated its guidance, raising the lower end of key ranges, and addressed regulatory changes in Brazil affecting certain antimicrobials. Phibro also launched a sustainable solutions platform and strengthened liquidity by increasing its revolving credit facility by $125 million.

Market Beat

Phibro Animal Health Q3 Earnings Call Highlights

ELAN

ECO Animal Health Group (LON:EAH) shares fell below their 200-day moving average of GBX 98.93, trading as low as GBX 92 before closing at GBX 93.78. The company has a market cap of £62.83 million and a price-to-earnings ratio of 21.33. Analysts maintain a "buy" rating with an average price target of GBX 160. Despite the current dip, the company is recognized for its veterinary pharmaceuticals and has a strong R&D pipeline.

Elanco Animal Health

ECO Animal Health Group (LON:EAH) Share Price Crosses Below 200 Day Moving Average   - Here's Why

FSLY

PLNT

BETR

SHAK

AMPX

GPGI

AOSL

INSM

Fastly(FSLY) fell 38.23%, with a trading turnover 942.9 Million USD, and a year-to-date rose 91.6%. Planet Fitness - CL(PLNT) fell 31.19%, with a trading turnover 741.3 Million USD, and a year-to-date fell 59.4%. Better Home &amp; Finance(BETR) fell 28.51%, with a trading turnover 85.9 Million USD, and a year-to-date fell 6.3%.

- The Nasdaq Composite Index fell by 0.13% but has increased by 11% year-to-date.  
- The S&P 500 Index dropped 0.38%, with a year-to-date gain of 7.2%, while the Dow Jones Index decreased by 0.63%, accumulating a 3.2% increase this year.  
- Fastly experienced a significant decline of 38.23%, despite a 91.6% increase year-to-date, while Planet Fitness and Better Home & Finance dropped by 31.19% and 28.51%, respectively.

Top Gainers&Losers

Fastly

Planet Fitness - CL

Better Home & Finance

Shake Shack

Installed Building Products

Amprius Tech

Alpha &Omega

Insmed

Top 10 US Stock Losers (5.7)

Phibro Animal Health shares are trading lower. The company reported Q3 financial results.

benzinga_article

Earnings Watch

Phibro Animal Health | 8-K: FY2026 Q3 Revenue Beats Estimate at USD 383.5 M

Phibro Animal Health Corporation Reports Third Quarter Results, Updates Financial Guidance | PAHC Stock News

StockTitan

Phibro Animal Health Corporation Reports Third Quarter Results, Updates Financial Guidance | PAHC Stock News

Phibro Animal Health Corporation has amended its credit agreement, increasing its revolving credit commitment from $310 million to $435 million. This enhancement aims to improve the company's financial flexibility and liquidity for operational needs and strategic initiatives. The latest analyst rating for PAHC stock is a Hold with a price target of $62.00. Spark's AI Analyst rates PAHC as Neutral, citing strong financial performance but high leverage. Phibro operates in the animal health industry, supporting livestock health and productivity.

Tip Ranks

Phibro Animal Health Expands Revolving Credit Facility Commitment

Phibro Animal Health(PAHC.US)

Phibro Animal Health posts transcript of Q3 2026 earnings call

Phibro Animal Health Q3 Earnings Call Highlights

ECO Animal Health Group (LON:EAH) Share Price Crosses Below 200 Day Moving Average - Here's Why

Top 10 US Stock Losers (5.7)

Phibro Animal Health shares are trading lower. The company reported Q3 financial results.

Phibro Animal Health | 8-K: FY2026 Q3 Revenue Beats Estimate at USD 383.5 M

Phibro Animal Health Corporation Reports Third Quarter Results, Updates Financial Guidance | PAHC Stock News

Phibro Animal Health Expands Revolving Credit Facility Commitment

Trending